Design Therapeutics (DSGN) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, gaining 63.6% versus a loss of 42.9%. Over five years, DSGN leads with a -18.2% price change compared with -76.4% for IVA. Inventiva S.A. American Depository Shares is the larger company by market cap ($746.5 million vs $729.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | IVA |
|---|---|---|
| Share price | $11.65 | $3.16 |
| Market cap | $729.08M | $746.46M |
| 1-day change | +1.39% | -4.82% |
| YTD return | +24.20% | -32.04% |
| 1-year return | +63.62% | -42.86% |
| 5-year return | -18.25% | -76.42% |
| EPS (TTM) | $-1.18 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $7.98 |
| 52-week low | $5.28 | $3.11 |
| Distance from 52-week high | -32.46% | -60.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +86.35% | +381.01% |
| Average volume | 604.06K | 1.40M |
| Shares outstanding | 62.58M | 236.22M |
| Employees | 55 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed IVA by 106.5 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
DSGN vs IVA FAQ
Which is bigger, Design Therapeutics or Inventiva S.A. American Depository Shares?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $746.46M compared with $729.08M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or IVA?
DSGN returned +63.62% over the past 12 months, compared with -42.86% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.